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Abstract
Background: The impact that distal urolithiasis has on patients can be devastating in terms of discomfort, pain,
and overall therapy cost. Traditional first-line treatment for ureteral stone less than 5mm has been
conservative therapy consisting of watchful waiting with the main focus placed on pain management. Larger
stones in the range of 5mm-10mm have a significantly smaller chance of spontaneous stone expulsion with
conservative therapy, many times requiring more invasive therapies such as single wave lithotripsy and
uteroscopy. Although these invasive procedures are classified as “minimally invasive”, and have advanced
considerably in terms of technology and technique over the past 20 years, they still carry with them risks and a
high cost to the patient. Over the years, researchers have isolated an abundance of alpha receptors in the distal
ureter similar to those in the male prostate. The blockage of these receptors in the presence of benign prostatic
hypertrophy, causes relaxation of the prostate thus increasing the ease by which voiding occurs decreasing the
intra-luminal pressure. Likewise, the alpha 1 receptors present in the distal ureter have similar implications to
that of the prostate in terms of ureteral relaxation, theoretically increasing the possibility for stone expulsion
and reducing renal colic caused by the increased peristaltic movement in the presence of a kidney stone.
Hypothesis: The administration of the off-label use of tamsulosin with traditional conservative urolithiasis
therapy will increase the facilitation in the presence of radiographically proven distal ureteral calculi in adults
when compared to traditional conservative therapy.
Study Design: Exhaustive search of available medical literature.
Methods: An exhaustive literature search was performed using three main search databases: Medline- Ovid,
CINAL, and PubMed. The search terms: Urolithiasis, tamsulosin, and Randomized Controlled trial were used
with a limit to retrieve studies published after 2007.
Results: A total of five articles addressing evaluating the use of 0.4mg tamsulosin versus conservative therapy
were used during this study. The primary endpoint addressed, was stone expulsion, because of its direct
correlation with therapeutic success. Other clinically relevant and important endpoints such as: total time
until stone expulsion, pain, and medication side effects were also evaluated in order to appraise the
effectiveness of tamsulosin in the presence of distal ureteral stone.
Conclusion: All of the articles evaluating the first-line therapy of tamsulosin in the presence of
radiographically proven urolithiasis of less than 1 cm in the adult population illustrated a statistically
significant increase in stone expulsion in the 0.4 mg tamsulosin daily administration groups versus
conservative therapy groups. Additionally, the secondary endpoints addressed in this study: time to expulsion,
pain, and side effects of medication administration demonstrated consistent evidence suggesting positive
clinical effectiveness with the use of tamsulosin as a first-line therapy.
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Abstract   
 
Background:  The impact that distal urolithiasis has on patients can be devastating in terms of 
discomfort, pain, and overall therapy cost.  Traditional first-line treatment for ureteral stone less than 
5mm has been conservative therapy consisting of watchful waiting with the main focus placed on pain 
management.  Larger stones in the range of 5mm-10mm have a significantly smaller chance of 
spontaneous stone expulsion with conservative therapy, many times requiring more invasive therapies 
such as single wave lithotripsy and uteroscopy.  Although these invasive procedures are classified as 
“minimally invasive”, and have advanced considerably in terms of technology and technique over the 
past 20 years, they still carry with them risks and a high cost to the patient.   
Over the years, researchers have isolated an abundance of alpha receptors in the distal ureter similar to 
those in the male prostate.  The blockage of these receptors in the presence of benign prostatic 
hypertrophy, causes relaxation of the prostate thus increasing the ease by which voiding occurs 
decreasing the intra-luminal pressure.  Likewise, the alpha 1 receptors present in the distal ureter have 
similar implications to that of the prostate in terms of ureteral relaxation, theoretically increasing the 
possibility for stone expulsion and reducing renal colic caused by the increased peristaltic movement in 
the presence of a kidney stone.   
 
Hypothesis:  The administration of the off-label use of tamsulosin with traditional conservative 
urolithiasis therapy will increase the facilitation in the presence of radiographically proven distal 
ureteral calculi in adults when compared to traditional conservative therapy. 
 
Study Design:  Exhaustive search of available medical literature 
 
Methods:  An exhaustive literature search was performed using three main search databases: Medline- 
Ovid, CINAL, and PubMed.  The search terms: Urolithiasis, tamsulosin, and Randomized Controlled 
trial were used with a limit to retrieve studies published after 2007.   
 
Results:  A total of five articles addressing evaluating the use of 0.4mg tamsulosin versus conservative 
therapy were used during this study.  The primary endpoint addressed, was stone expulsion, because of 
its direct correlation with therapeutic success.  Other clinically relevant and important endpoints such 
as: total time until stone expulsion, pain, and medication side effects were also evaluated in order to 
appraise the effectiveness of tamsulosin in the presence of distal ureteral stone.  
 
Conclusion:  All of the articles evaluating the first-line therapy of tamsulosin in the presence of 
radiographically proven urolithiasis of less than 1 cm in the adult population illustrated a statistically 
significant increase in stone expulsion in the 0.4 mg tamsulosin daily administration groups versus 
conservative therapy groups.  Additionally, the secondary endpoints addressed in this study: time to 
expulsion, pain, and side effects of medication administration demonstrated consistent evidence 
suggesting positive clinical effectiveness with the use of tamsulosin as a first-line therapy. 
 
Keywords:  Randomized control trial, distal ureteral stone, urolithiasis, medical expulsive therapy, 
tamsulosin. 
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Off-label Use Tamsulosin in the Presence of Uncomplicated 
Radiographically Proven Distal Urolithiasis 
 
Introduction and Background 
 
 The Oxford Text Book of Medicine states that urolithiasis is certainly not a new urologic 
pathology.  The earliest evidence of the disorder is the stones found in mummies entombed in the 
predynastic Egyptian era, around 4000 BC.  More recently, in the last two centuries, urolithiasis was 
highly associated with children, particularly boys, and was thought be correlated with poor nutrition.  
Although urolithiasis, secondary to poor nutrition, in Western countries has declined significantly over 
the past 100 years, an area of the Middle East which stretches from Jordan, through Iraq, Iran, and the 
Indian subcontinent to the furthest reaches of South-East Asia still has a considerable number of cases 
of urolithiasis stemming from poor nutrition.1 
Although the epidemiology and etiology of urolithiasis has shifted over the last 100 years away 
from children and towards the adult population, and from poor nutrition to dietary over indulgence, 
respectively, alas urolithiasis is a is still present today.  A 2006 article printed in the American 
Academy of Family Physicians’ peer reviewed journal, reports that American men are twice as likely 
as women to develop calculi, with the first episode occurring at an average age of 30 years.  Women 
have a bimodal age of onset, with episodes peaking at 35 and 55 years.  Without preventive treatment, 
the recurrence rate of calcium oxalate calculi increases with time and reaches 50 percent at 10 years. 2  
The research’s insinuation that the trend in urolithiasis epidemiology is towards a younger patient 
population and to crossing gender boarders is concerning both at the patient level and on the macro 
scale.   
Urolithiasis continues to be a significant problem today is seen in a variety of clinical settings.  
In 2003, Dellabella et al reported that urolithiasis affected about 8% to15% of the population in Europe 
and North America and represented the most common condition seen by urologists in the emergency 
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setting.3  To further illustrate the clinical problem that urolithiasis poses, in 2006, Pearle et al 
conducted a study entitled Urologic Diseases in America Project: Urolithiasis, that looks at the overall 
effect that symptomatic ureteral stones have on the macro level.  The study stated physician office visit 
rates for patients with a primary diagnosis of urolithiasis, as determined by the National Ambulatory 
Medical Care Survey, were stable between 1992 and 1996, and then increased significantly in 1998 
and 2000.  Ultimately, their study concluded that the patient visit rate was 43% higher in 2000 than it 
had been in 1992, and the total number of visits almost doubled between 1992 and 2000, increasing 
from 950,000 to 1,825,000.4  The implications of the fore mentioned statistics are both, overwhelming 
and significant, when taking into account patient pain, sequelae of extended urolithiasis, and the 
medical cost accrued from the beginning of symptoms to stone expulsion.  In 2000 alone, the total 
annual direct cost of urolithiasis in the United States was estimated at nearly $2.1 billion, including 
$971 million for inpatient services, $607 million for physician office and hospital outpatient services, 
and $490 million for emergency room services.5  The obvious question that arises after assessing these 
statistics is: Is there a better, non invasive, cost effective, therapy that can be incorporated in the 
passage of urolithiasis? 
Urolithiasis and nephrolithiasis pathophysiology is complex and may arise from a variety of 
medical co-morbidities and dietary factors, but the fundamental pathologic aspect of the disorder is the 
supersaturation of urine with stone-forming calcium salts collected within the working units of the 
kidney.6  The stones eventually follow the same anatomic pathway as urine, and travel distally down 
the ureter many times causing the classic symptoms of renal colic and hematuria.  Some patients may 
present asymptomatically or have atypical symptoms such as vague abdominal pain, acute abdominal 
or flank pain, nausea, urinary urgency or frequency, difficulty urinating, penile pain, or testicular pain.7  
Symptomatic urolithiasis can be an excruciatingly painful medical problem depending on the size of 
the stone and is usually is dealt with in the emergency room.  
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Current standard treatment for urolithiasis follows the non-invasive to more invasive spectrum 
depending on the size of the stone and the location within the ureter.  Watchful waiting with 
conservative analgesic therapy is the first-line in urolithiasis treatment.  Non steroidal anti-
inflammatory medication, such as ketorolac and diclofenac,  have the possible advantage of decreasing 
ureteral smooth muscle tone, thereby directly treating the mechanism by which pain is thought to occur 
namely, ureteral spasm.8  The contemporary guidelines state that stones 0.5 cm or less in diameter have 
an 80% chance of spontaneous passage, equal to 0.5 centimeters the chance is 20-50%, and for stones 
greater than 0.5 cm the patient should consult an urologist.9  On the more invasive end of the spectrum, 
therapies such as single wave lithotripsy, ureteroscopic removal, and finally opened uterolithotomy 
have been the traditional second and third line treatments for urolithiasis.  Although there have been 
vast improvement in the last 20 years with the above mentioned minimally invasive procedures for 
ureteral stones, there has also been a significant increase in treatment costs.3  The cost that Dellabella 
et al are referencing are not only financial, rather the overall cost to the body in terms of surgical 
infection, post intervention pain, and other possible post surgical sequelae.  
In 2004, Sigala et al published a paper entitled Evidence for the presence of alpha 1 
adenoreceptors subtypes in the human ureter, showing increased density of alpha 1a adrenergic 
receptors in the smooth muscle of the ureter.10  The implication of their research is crucial in terms of 
urolithiasis treatment.  Urolithiasis migration down the ureter is modulated by the sympathetic nervous 
system via the alpha 1 receptors and the movement of the stone is facilitated by peristaltic movement 
of the tubular ureter.  The pain pathway of urolithiasis arises from the increased intraureteral pressure 
and peristaltic muscle movements in the presence of urolithiasis.  Thus, sympathetic alpha adrenergic 
antagonists such as tamsulosin have the ability to inhibit basal tone, peristaltic amplitude and 
frequency, dilating the urethral lumen and decreasing intraureteral pressure, thereby increasing the rate 
of fluid transport and ultimate facilitation of the passage of the stone.11 12 
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After the general assessment of intense patient discomfort, risk versus benefit of minimally 
invasive urologic procedures, and overall cost of urolithiasis treatment, the question still begs: if an 
adjunctive therapy in the form of an off-label benign prostate hypertrophy medication like tamsulosin 
could help with the passage of ureteral stones, should it not be prescribed?  This paper will help to 
answer that question by primarily analyzing the direct correlation of therapeutic success, ureteral 
expulsion.   
Purpose and Significance of Study 
      
A systematic review of evidence based medicine articles was performed to assess and evaluate 
the efficacy of the alpha 1a-d receptor antagonist tamsulosin in the presence of distal ureteral stones, 
specifically addressing the main endpoint: stone expulsion.  Other clinically significant secondary 
endpoints included: time to expulsion, pain, and medication administration side effects, will further 
illustrate the effectiveness of tamsulosin administration in the presence of distal urolithiasis.  Each of 
the studies assessed in this paper measured the 0.4 mg daily dose of tamsulosin with conservative 
treatment against conservative treatment only in the adult population with radiographically proven 
distal urolithiasis. 
There have been significant advances in minimally invasive treatments of urolithiasis 
expulsion; however, they have not come without a significant cost to the patient.  Along with assessing 
these minimally invasive therapies, researchers over the past several years have evaluated various 
medication expulsion therapies using off-label medications with varying degrees of success. 
The ultimate goal and purpose of this paper is to further continue the evaluation of MET as a 
first-line urolithiasis treatment modality by assessing the off-label use of tamsulosin in the presences of 
distal ureteral stones in the adult population.  The medication’s mechanism of action, blockage of the 
alpha receptor 1a-d, theoretically makes tamsulosin an excellent medication choice when considering 
the abundance of alpha 1 receptor sites in the distal ureter.  This systematic review will help evaluate 
 12 
this question with the use of statistically significant evidenced based medical articles by comparing the 
addition of tamsulosin with traditional conservative therapy against conservative therapy only, by the 
evaluation of the main endpoint: stone expulsion and secondary endpoints including: time to stone 
expulsion, medication side effects, and evaluation of pain. 
The significance of proving the effectiveness of tamsulosin as a first-line therapy in distal 
urolithiasis therapy has the potential to drastically improve overall patient comfort by increasing stone 
expulsion, decrease the episodes of renal colic, time to expulsion, and reducing patient costs. 
Methods 
 
 The study is a comprehensive systematic literature review.  An exhaustive literature search was 
performed using three main search databases: Medline- Ovid, CINAL, and PubMed.  The search 
terms: Urolithiasis (26515), tamsulosin (792), and Randomized Controlled Trial (276,289) were used 
to retrieve studies published after 2007.  These search criteria tallied a total of eight articles pertaining 
to the use of tamsulosin in the presence of urolithiasis, three of which were excluded because the 
tamsulosin administration was in regards to a second-line treatment after single wave lithotripsy. 
The inclusion criteria includes for this study were: adult population with radiographically 
proven uncomplicated urolithiasis in the distal third of the ureter, male and female subjects, and that 
the study be at least double armed (with one arm receiving both 0.4mg of tamsulosin combined with 
conservative therapy daily and the other arm receiving conservative treatment only).  Furthermore for 
inclusion, the study needed to be randomized with a JADAD score of at least two, primary outcomes 
of stone expulsion, time to expulsion. 
Excluded were: non- randomized studies, meta-analyses, systematic reviews, and tamsulosin 
administration in the presence of post lithotripsy.  Studies with patients with the following co- 
morbidities were also excluded: urinary tract infection, marked hydronephrosis, multiple stones, 
pregnancy, concomitant alpha blocker therapy, history of ureteral stricture, and fever. 
 13 
Other statistically significant articles, urological texts, and reputable medical resource websites 
were also reviewed and examined for their didactic and clinical importance and used as reference 
material in this study. 
Results 
 
 This systematic review, focusing on the first-line treatment with tamsulosin in the presence of 
radiographically proven uncomplicated distal urolithiasis, evaluated a total of five relevant articles 
found with the search criteria laid out above.  These articles assessed the administration of tamsulosin 
with CT versus conservative therapy, traditionally defined as watchful waiting with the main focus on 
symptomatic pain control.  Moreover, the appraised literature specifically spotlighted the adult 
population ranging from ages 18-65 years of age.   
 Wang, Huang, and Chang evaluated the clinical role of the alpha 1a-1d specific blocker, for 
medical expulsive therapy of symptomatic lower ureteral stones with a three armed study assessing the 
effectiveness of the alpha blockers: tamsulosin and terazosin.  The prospective randomized study 
consisted of 95 patients greater than 18 years of age both male and female, with radiographically 
proven distal urolithiasis at 6.5mm in diameter for all groups with no statistical significant difference 
(P=0.99) between the size of the stone nor the differences in age or gender between the three groups.  
Patients were then randomly divided by the urologist who treated them in the emergency room into 
three groups: group 1: 32 patients received 0.4mg tamsulosin daily, group 2: 32 patients received 2mg 
terazosin daily, and the third group: 31 patients acted as controls (conservative therapy only).  All 
groups received conservative therapy consisting of ketorolac 10 mg three times per day, and were 
allowed 0.2 mg sub lingual buprenorphine as needed, and were encouraged to stay hydrated throughout 
the whole study.  The three major outcomes that the study looked at were stone expulsion, time to 
stone expulsion, and the number of colic episodes as measured by pain medication administration.   
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Stone expulsion was observed in 26 out of 31 patients (81%) in group one, 25 out of 32 patients 
(78%) in group 2, and 17 out of 31 patients in group three (55%).  A statistically significant difference 
was seen between groups 1 and 3 and 1 and 2 (P=0.05 and P= 0.02, respectively).   
Time to stone expulsion was the next endpoint observed in the Wang et al. study.  The average 
time to expulsion for group one was 6.3 +/- 2.4 days (ranging from 3-12 days), group 2 was 6.3 +/-2.1 
day (ranging from 3-11 days), and group 3 10.1 +/- 3.0 days (ranging from 6-14 days).  A statistically 
significant difference was seen between groups 1 and 3 and 1 and 2 (P=<0.05 and P= <0.0001, 
respectively). 
Pain as measured by mean ketorolac consumption was group 1: 231mg +/- 112mg group 2: 256 
+/- 112mg, and finally group 3: 347 +/- 106.  A statistically significant difference was seen between 
groups 1 and 3 and 1 and 2 (P=<0.0001 and P= <0.001, respectively). 
One patient in the tamsulosin group reported unspecified side effects, as did five patients in the 
terazosin group, but all patients completed the study. 
The authors concluded that first line MET proved to be safe and effective with whom watchful 
waiting is appropriate, particularly with the administration of 0.4 mg tamsulosin daily.  The treatment 
was shown to be safe and effective as shown by the low incidence of side effects, increased stone 
expulsion rate, and reduced expulsion time.  Pain ratio was also significantly reduced in the patients 
being treated with MET.12 
Lojanapiwat, Kochakarn, Suparatchatpan, and Lertwuttichailkul evaluated the use of 
tamsulosin in the presence of uncomplicated distal urolithiasis.  The study was a 28 day trial 
comparing two different doses of tamsulosin with conservative therapy versus conservative therapy 
alone.  The study was a randomized control study consisted of 75 adult Asian patients with 
radiographically proven urolithiasis in the distal ureter with stone size ranging from 4mm –10 mm in 
diameter.  Patients were block randomized into three groups by the assistant nurse.  Group 1 was the 
control and received 50 mg of sodium diclofenac twice per day for 10 days.  Group 2 also received 50 
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mg of sodium diclofenac twice per day with the addition of 0.2 mg tamsulosin per day for 28 days, or 
until expulsion of the stone.  Group 3 also received 50 mg of sodium diclofenac twice per day with the 
addition of 0.4 mg tamsulosin per day for 28 days, or until expulsion of the stone.  There was no 
statistically significant difference between group one, group two, and group three in regards to age, 
gender, stone size (6.70+/-1.66, 6.42+/-1.48, and 6.26 +/-1.27 respectively).  The major outcomes that 
the study looked at were stone expulsion and time to stone expulsion.   
 Stone expulsion was observed in 1 out of 25 patients (4%) in the CT group, 10 out of 25 
patients (40%) in the low dose tamsulosin group, and 17 out of 25 patients in the 0.4mg tamsulosin 
group (68%).  A statistically significant difference was seen between groups 1 and 2 and 1 and 3 
(P=<0.001 and P= <0.001, respectively), but no significant difference between the different doses of 
tamsulosin.   
Mean times to stone expulsion were the next endpoints observed in the study.  The average 
time to expulsion for the CT group ranged was 23.00 days, low dose tamsulosin group was 9.30 days, 
and the group 3 10.76 days.  A statistically significant difference was seen between groups 1 and 2 and 
1 and 3 (P=<0.001 and P= <0.001, respectively), but showed no statistical difference between the 
tamsulosin groups. 
The authors concluded that both the low dose and regular dose of tamsulosin were good first-
line therapies for patients with ureteric stones of 4mm-10mm.  Furthermore, the medication will help 
patients achieve a stone free status and reduce expulsion times with minimal side effects.  The authors 
went on to say that although the low dose option of tamsulosin would be an adequate first-line therapy 
for the Asian patient population, it is worthwhile considering that they tend to have a lower mean body 
weight compared with Western patients.13 
 Agrawal M, Gupta M, Gupta A, Agrawal A, and Sarkari evaluated the uses the alpha blockers: 
tamsulosin and alfuzosin against placebo in the presence of radiographically proven uncomplicated 
distal urolithiasis with the stone less than 1 cm.  The prospective randomized study consisted of 102 
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adult patients, held to the same above mentioned exclusion criteria, randomized to three groups: group 
one (34 patients), those receiving 0.4 mg tamsulosin daily with conservative therapy, group two (34 
patients), receiving 10 mg alfuzosin daily with conservative therapy, and group three (34 patients), 
receiving placebo (conservative therapy only).  Conservative therapy was defined as the administration 
of diclofenac injections intramuscularly as needed for pain.  The average stone size for groups one, two 
and three was comparable: 6.17, 6.70, and 6.35, respectively.  Outcomes followed were, spontaneous 
passage of the stone, time of stone expulsion, pain measured by total diclofenac dosage, and number of 
pain episodes. 
 Stone expulsion was observed in 28 out of 34 (82.3%) patients in the tamsulosin group, 24 out 
of 34 (70.5%) in the alfuzosin group, and 12 out of 34 (35.2%) in CT group.  Both the tamsulosin and 
alfuzosin groups had a statistically significant greater stone expulsion than with the CT group (P=0.008 
and P=0.001, respectively), but no statistical significance existed between the alpha blocker groups (P= 
0.4). 
 Stone expulsion time was 12.3 days in the tamsulosin group, 14.5 days in the alfuzosin group, 
and 24.5 days in the control group.  The tamsulosin and alfuzosin groups had statistically significantly 
shorter expulsion time compared with the control group (P=0.003 and P=0.001, respectively), but there 
was no significant difference between the different alpha blockers (P=0.25). 
 The mean number of pain episodes for the tamsulosin and alfuzosin groups was 0.58 and 0.82, 
respectively, significantly less that in the control group’s 5.5 episodes.  In terms of average diclofenac 
administration during the trial, the tamsulosin group required an average of 0.88 injections, the 
alfuzosin group required an average of 1 injection, and the control group receiving CT averaged 6.2 
injections. 
 The authors concluded that the study proved tamsulosin and alfuozosin administration to be 
significantly superior to conservative therapy in resolving distal urolithiasis, reduction in time to 
expulsion, and providing pain relief.14 
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 Porpiglia, Fiori, Ghingone, Vaccino, Billia, Morra, Rangi, and Scarpa assessed the use of 
tamsulosin with CT against conservative therapy only after the failure of a previous 10 days MET 
cycle consisting of tamsulosin and delfacort.  The study was 10 days, at the end of which outcomes 
including stone expulsion, time to expulsion, number of colic episodes, and amount of analgesia used 
were assessed.  If no stone expulsion occurred after the trial, invasive expulsion measures by way of 
ureteroscopy were performed in order to prevent extended urolithiasis sequelae.   
The prospective randomized study included 91 adult patients (tamsulosin and the control 
groups’ mean age 46 and 51 years old, respectively) with radiographically proven uncomplicated 
urolithiasis (tamsulosin and control groups’ mean stone size 5.93 and 6.03, respectively).  The above 
mentioned exclusion criteria included for this study was used.  The patients were broken up in to two 
study groups: Group A (46 patients) receiving 0.4mg tamsulosin, and group B (45 patients) acting as 
control receiving only conservative therapy.  Both groups received intramuscular injections of 75 mg 
of diclofenac for as needed for pain. 
Stone expulsion was observed in 37 out of 46 (80%) patients in the tamsulosin group, and 22 
out of 45 (49%) in the control group.  The difference between stone expulsion between the two groups 
was statistically significant (P=<0.01). 
Time to stone expulsion for groups A and B showed no statistically significant difference 
between the groups (P=>0.05) with a mean time of 7.1 and 5.9 days, respectively. 
The mean number of acute renal colic episodes observed for the two groups was not 
statistically significant (P=>0.05)were 1.39 and 1.12, respectively.  
 The mean analgesic administration of the tamsulosin group and control group were 122.7mg 
and 127.4mg, respectively and was not statistically significant (P=>0.05). 
 The authors concluded that the administration of 0.4mg of tamsulosin in the presence of distal 
urolithiasis along with conservative therapy significantly increased the expulsion of stones.  They went 
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on to comment that the data collected during this study showed that a duration of MET up to 20 days 
was useful in the treatment of distal urolithiasis.15 
 Abdel-Basir Sayed et al evaluated the role of tamsulosin in the first- line medical expulsive 
therapy in the presence of distal urolithiasis.  The randomized study consisted of 90 patients greater 
than 18 years of age both male and female, with radiographically proven distal urolithiasis with a mean 
stone size of 6.4mm and 6.8mm for the two groups and no statistically significant difference between 
sizes of stone.  Patients were then randomly divided into two groups: group A: 45 patients received 
100mg of diclofenac on an as needed basis for pain and a week of 250 mg levofloxacin, group B: 45 
patients received the same conservative treatment as group A, but 0.4 mg of tamsulosin was added.   
The three major outcomes that the study looked at were stone expulsion, time to stone expulsion, and 
the number of colic episodes as measured by pain medication administration.   
Stone expulsion was observed in 23 out of 45 patients (11%) in CT group and 40 out of 45 
patients (88.9%) in the tamsulosin group.  A statistically significant difference in stone expulsion was 
observed between the two groups (P=0.001).   
Time to stone expulsion was the next endpoint measured.  The average stone expulsion time for 
the CT group ranged was 12.53 +/- 2.12 days (ranging from 6-22 days) and the tamsulosin group was 
7.32 +/-0.78 day (ranging from 6-11 days).  A statistically significant difference was seen between the 
two groups (P= 0.04). 
Mean analgesic use in the CT group was: 2.78 vials +/- 2.7 vials (range 0-10 vials) and the 
tamsulosin group: 0.14 +/- 0.5 vials (range 0-2 vials).  A statistically significant difference was seen in 
analgesic medication administration between the groups (P=<0.0001). 
The number of colic pain episodes was statistically significantly lower in tamsulosin Group 
compared to CT group (1.53 +/- 0.25 versus 2.47 +/- 1.41 with a P=0.003). 
The study stated that there were no reported cases of medication side effects in either group. 
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The authors concluded that the use of tamsulosin in the facilitation of passing distal ureteral 
stones and associated need for analgesics was an effective and safe first-line treatment option.16 
 
Discussion 
 
 The objective of this systematic review is to assess the off-label effectiveness of urolithiasis 
expulsion with the selective alpha 1a-d antagonist tamsulosin plus conservative therapy in the adult 
population with radiographically proven uncomplicated urolithiasis in the distal ureter versus the 
current first-line treatment modality of conservative therapy alone consisting of watchful waiting with 
symptomatic pain control.  Besides the primary endpoint of the study, secondary endpoints including: 
time to stone expulsion, renal colic episodes, and side effects, were assessed.  These four endpoints 
were chosen as the focus of this systematic literature review because of their potential positive clinical 
ramification in the presence of urolithiasis. 
 Medical expulsion therapy in the presence of kidney stones has been the focus of numerous 
international urologic studies in years past, with the goal being recognition of the most effective 
medication to facilitate stone expulsion, while taking into account potential risks involved with the 
medications.  Several medications and combinations of medications including calcium channel 
blockers and alpha adrenergic antagonists, with or without steroids, have been used to aid in the 
spontaneous passage of ureteral calculi 17.  The decision to examine the off-label uses of these 
medications as a first-line urolithiasis therapy came about for several reasons, the most important being 
the comfort of the patient and overall goal of relieving an intensely painful disorder by increasing the 
likelihood of stone expulsion via pharmacologic intervention, before graduating to invasive stone 
expulsion procedures.   
Results from the five appraised articles in this study illustrate an overwhelmingly positive 
result in the efficacy of stone expulsion with the administration of tamsulosin in the presence of distal 
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urolithiasis.  In addition, the secondary endpoints evaluated: time to expulsion, pain, and medication 
side effects also demonstrated to be both statistically significant and clinically important. 
Stone expulsion 
Stone expulsion is the main endpoint addressed in this article because of its direct correlation 
with therapeutic success.  The passage of distal ureteral stones, in the above outlined patient 
population, was statistically significantly greater in all studies when comparing tamsulosin plus 
conservative therapy to conservative therapy alone(see Table 1).   
Upon further tabulation of the data collected in this study, the number needed to treat was also 
evaluated as to better assess the clinical significance of tamsulosin administration as a first-line 
therapy.  The NNT calculation, ranging from 1.52 to 3.30 in the five studies, illustrates impressive 
ratio of tamsulosin administration to stone expulsion, further demonstrating the effectiveness of this 
therapy (see Table 1). 
The implications of the consistent positive data findings throughout recent clinical trials are 
important on the individual patient level in regards to a greater expectation of spontaneous stone 
expulsion, thus significantly increasing patient comfort by the reduction of associated intense renal 
colic, reducing the chance of prolonged ureteral stone sequelae, reducing invasive urologic procedures, 
et cetera.  On the macro level, the relief of symptomatic urolithiasis by non invasive stone expulsion 
also has a strong impact on society as a whole in regards to cost and efficient delegation of medical 
personnel and resources. 
Time until stone expulsion 
Total time from renal colic symptoms until stone expulsion is a secondary, although, essential 
endpoint also addressed in this study.  The intense nature of symptomatic ureteral stones and amount 
of time patients have to experience that pain is an important clinical consideration when addressing the 
decision to use the current conservative treatment versus treating kidney stones with the off-label use 
of tamsulosin in addition to the conservative treatment.   
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In four of the five appraised articles, a statistically significant reduction in expulsion time was 
demonstrated with the use of tamsulosin versus conservative therapy (Table 2).  The implication of this 
consistent data finding is certainly an important assessment tool when taking into account the comfort 
of the patient, more specifically how much less time patients have to experience pain.  
Pain 
 Pain is arguably, the most important clinical characteristic concomitant with ureteral stones.  
The difficulty for researchers lies in the actual measurement of the study participant’s subjective 
definition of pain.  Regardless of the difficultly of measurement, pain remains an essential part of the 
presentation of kidney stones, and is thus addressed in this systematic review. 
Pain was addressed in all five of the studies evaluating the effectiveness of tamsulosin in the 
presence of distal ureteral stones, but was subject of varying descriptions and findings.  In only four of 
the five studies, was pain formally addressed with a statistical analysis.  The quantification 
measurement that was evaluated in these studies and that on which this systematic review chose to 
focus was the total amount of medication administered during the study, more specifically the 
administration of non steroidal anti-inflammatory medication because of its current use as a first line 
treatment in ureteral stone symptomatic pain control.  The studies performed by: Sayed et al, Agrawal 
et al, and Wang et al all showed that statistically significantly less NSAID medication was 
administered with the use of tamsulosin plus CT when compared to conservative therapy alone.  
Porpiglia et al showed no statistically significant difference in NSAID administration between the two 
groups (see Table 3 for full results).  Although the measurement is not perfect, there is certainly 
compelling evidence that informs the use of tamsulosin in pain reduction during urolithiasis episodes. 
Side effects of medication administration 
 The final secondary endpoint evaluated was side effects caused by tamsulosin administration in 
each of the five studies assessed.  As with any medication, the risk to benefits ratio must be evaluated 
before administration.  Being a first-line treatment in the relief of BPH symptoms, the medication’s 
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mechanism of action is as an alpha 1a-d antagonist, thus the medication does, theoretically, have side 
effect potential.  Common side effects occurring happening in greater than 10% of patients are the 
following: hypotension/orthostatic hypotension, headache, dizziness, abnormal ejaculation, and 
infection.18  
 All of the five articles evaluated in this systematic review addressed side effects in their 
research, more specifically the lack of side effects.  Interestingly, in all of the five studies, no patient 
pulled out of the study due to side effects.  Furthermore, of those five studies, in three studies: Sayed et 
al, Porpiglia et al, and Lojanapiwat et al patients did not experience any side effects.  The remaining 
two studies, Agrawal et al and Wang et al experienced one “adverse side effect” and “mild side 
effects”, respectively, but did not report on what specifically the side effects were only commenting 
that all patients finished in spite of them.  The suggestion of this data is certainly compelling when 
taking into account the risk versus benefit of tamsulosin as an off-label use. 
Cost 
 Thus far, consistent positive evidence for the off-label therapeutic use of tamsulosin in the 
presence of uncomplicated distal ureteral stones has been illustrated by statistically significant and 
clinically relevant data collection from recent articles.  The final concern that this systematic review 
will address is the cost of distal ureteral stones expulsive treatment in comparing MET to minimally 
invasive urologic procedures.   
The cost of treating urolithiasis is approximately 2.1 billion dollars per year 5, a staggering 
number to say the least.  Furthermore, in a 2008 Bensalah et al study assessing the cost-effectiveness 
of MET using tamsulosin with CT versus traditional watchful waiting observation with symptomatic 
pain alone control showed an $1132 cost advantage with MET using tamsulosin over traditional 
conservative observation ($1493 versus $2625, respectively) assuming the presumed 54%  increase in 
stone expulsion on MET.  The study went on to discuss the high cost of ureteroscopy ($4773) when 
compared to the low cost of tamsulosin administration ($2.08 per pill, $28 for 14 days, a normal MET 
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course) and stated even a 1% greater likelihood in stone passage with MET makes the therapy a cost 
effective strategy because it precludes the need for ureteroscopy which is 170 times more expensive 
than the cost of tamsulosin.19 
Limitations 
Although the evaluated articles support the administration of tamsulosin in the presence of 
radiographically proven distal urolithiasis in the adult population, and continuously suggests positive 
outcomes in regards to stone expulsion, decreased time to expulsion, decrease in pain, and few to no 
side effects, there were limitations to this review. 
 The first limitation of the study came about with the minimally specific nature of the ureteral 
stone size.  The inclusion criteria for these studies were generally a stone greater than 4-5 mm and less 
than 1cm, and the measurement was then averaged for statistical data tabulation.  Although there was 
no statistically significant difference between the experimental and control groups in terms of stone 
size in the included articles, in the future studies measuring specific stone sizes would aid the further 
assessment of tamsulosin administration.  
The second limitation came in the form of potential study biases.  In the five studies assessed, 
although all of the patients were randomized, yet there was little or no explanation as to the manner in 
which this was accomplished.  Additionally, none of the evaluated articles were multi-centered studies.  
With the addition of double-blinded studies and larger studies that incorporate numerous medical 
facilities, the power of these trials will grow and further prove the effectiveness of tamsulosin in the 
presence of distal ureteral stones. 
The figures outlining clinical success in the evaluated articles are compelling.  Although the 
evidence points to positive outcomes with tamsulosin administration, more specific clinical trials 
including double-blinded, multi-facility trials are warranted for the further evaluation of this off-label 
use. 
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Conclusion 
 
In conclusion, the main focal point of this systematic review was placed on stone expulsion in 
the presence of uncomplicated distal urolithiasis because of its direct correlation with therapeutic 
success.  This principal endpoint has been consistently proven in the adult population with current, 
reputable, and reproducible clinical trials.  Furthermore, additional clinically relevant data throughout 
the literature suggested strong evidence for a decreased time to stone expulsion, decreased pain, and a 
significantly increased cost-effectiveness with the addition of tamsulosin as a first-line therapy in the 
presence of distal ureteral stones.  Tamsulosin has proven clinically efficacious and has shown few to 
no side effects in the evaluated clinical trials indicating that it has an excellent risk to benefit ratio as a 
first-line therapy in all clinical settings.   
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Tables 
 
Table 1:   
Comparison chart of tamsulosin versus conservative therapy in the distal ureteral stone expulsion 
Study Expulsion (tamsulosin 
versus control, 
respectively) 
P value NNT 
Agrawal et al 82.3% vs 35.2% P=0.008 2.48 
Lojanapiwat et al 68.0% vs 4.0%, P= <0.001 1.52 
Wang et al 81.0% vs 55.0% P=0.05 3.30 
Sayed et al 88.9% vs 51.1% P=0.001 2.13 
Porpiglia et al 80.0% vs 49.0% P=<0.01 2.74 
 
 
 
Table 2: 
Comparison chart of tamsulosin versus conservative therapy in time to distal ureteral stone expulsion  
Study Time to Expulsion in days 
(tamsulosin versus control, 
respectively) 
P value 
Agrawal et al 12.3 days vs 24.5 days 
 
P=0.003 
Lojanapiwat et al 10.76 days vs 23.00 days P= <0.001 
Wang et al 6.3 +/- 2.4 days (ranging from 
2-12 days) vs 10.1 +/- 3.0 days 
(ranging from 1-14 days) 
P=<0.05 
Sayed et al 12.53 +/- 2.12 days 
(ranging from 6-22 days) vs  
7.32 +/-0.78 day (ranging 
from 6-11 days) 
P= 0.04 
Porpiglia et al 5.9 days vs 7.1 days P=>0.05 
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Table 3: 
Comparison chart of tamsulosin versus conservative therapy 
 
Study Pain measurement description P value 
Agrawal et al Total pain episodes- (T vs CT) 
0.58 vs 5.5  
 
Total diclofenac injections-  
(T vs CT) 
0.88 vs 6.2   
 
Reported statistically 
significant, but no P value was 
reported 
Lojanapiwat et al Renal colic episodes-  
No difference reported 
between the groups 
No P valuve reported reported 
Wang et al Mean analgesic dose  
(T vs CT) 
Buprenorphine administration- 
0.39mg vs. 0.39mg 
 
Ketorolac consumption- 
231mg vs 347mg 
 
Colic episodes 
1.97 vs 2.16 
 
 
P=>0.05 
 
 
P=0.0001 
 
 
P= >0.05 
Sayed et al Pain episode (T vs CT) 
1.53 vs 2.47 
 Number of analgesica vials 
used (T vs CT) 
2.78 vs 0.14 
 
 
P=0.003 
 
 
P=0.001 
Porpiglia et al No. acute renal colic  
(T vs CT) 
1.39 vs 1.12 
 
Total diclofenac (T vs CT) 
122.7 mg vs 127.4 mg 
 
P=>0.05 
 
 
 
P=>0.05 
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Table 4: Tamsulosin administration side effect 
 
Study Side effects Did all participants complete 
study? 
Agrawal et al “mild”- Dizziness(4), 
headache (5), Fatigue(2), 
Rhinitis(2), retrograde 
ejaculation(3) 
Yes 
Lojanapiwat et al No adverse effects reported Yes 
Wang et al One adverse effected  Yes 
Sayed et al None Yes 
Porpiglia et al None Yes 
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Table 5: Evaluated article table 
 
 
Author/  
Title/ 
Journal 
Yr.  
publish
ed 
Patients/  
Populatio
n 
Interventio
n 
Compariso
n 
Outcome
(s) 
Stud
y 
type 
Validi
ty 
(Jadad 
score) 
Comment
s 
Lojanapiwat 
et 
al/Effective
ness of 
Low-dose 
and 
Standard 
dose 
Tamsulosin 
in the 
treatment of 
Distal 
Ureteric 
Stones: a 
Randomized 
Controlled 
Study 
2008 75 Asian 
patients 
with 
4mm-
10mm 
Uretic 
stones on 
XR 
0.2 mg 
tamsulosin 
50 mg 
diclofenac 
BID  
Adequate 
hydration 
for 10 days 
0.4 mg 
tamsulosin 
50 mg 
diclofenac 
BID 
Adequate 
hydration 
for 10 days 
No A-
blocker 
50mg 
diclofenac 
BID 
Adequate 
hydration 
For 10 
days 
Expulsio
n, Time 
to 
expulsio
n 
 
RC
T 
3 Primarily 
looked at 
Asian 
populatio
n.  
Study 
showed 
decreased 
expulsion 
time, and 
shown 
safe. 68% 
passage 
with 0.4 
mg tam 
40% 
passage 
with 0.2 
mg tam  
4% 
passage 
with 
placebo 
Wang et 
al./Efficacy 
of an Alpha 
1 Blocker in 
Expulsion 
Therapy of 
Lower 
Ureteral 
Stones  
2008 95 
patients 
with 
radiograp
hic proof 
of <10 
mm stone 
0.4mg 
tamsulosin 
daily  
for 14 days 
2.0mg 
terazosin 
for 14 days 
Both 
groups 
received 
 10mg 
ketorolac 
TID, SL 
0.2 mg 
buprenorph
ine PRN, 
instructed 
to drink 2L 
10mg 
ketorolac 
TID, SL 
0.2 mg 
buprenorph
ine PRN, 
instructed 
to drink 2L 
H2O/day 
For 14 
days 
Expulsio
n rate, 
expulsio
n time, 
amount 
of pain 
med 
used 
RC
T 
3 Statistical
ly 
significan
t 
difference 
was seen 
in all 
three 
measurin
g 
parameter
s with  
tamsulosi
n and 
terazosin 
versus 
placebo 
in distal 
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H2O/Day urolithiasi
s 
SE 
experienc
ed, but all 
patients 
finished 
study 
 
Agrawal et 
al/ 
Prospective 
Randomized 
Trial 
Comparing 
Efficacy of 
Alfuzosin 
and 
Tamsulosin 
in 
Managemen
t of Lower 
Ureteral 
Stones 
 
2008 102 
patients 
w/ 
urolithiasi
s <1cm in 
distal 
ureter as 
seen by 
radiograp
hic proof 
0.4 mg 
tamsulosin 
daily 
3L of H2O, 
75 mg 
diclofenac  
injection 
PRN pain 
for up to 
four weeks 
10mg 
alfazosin 
QD 
3L of H2O, 
75 mg 
Diclofenac  
injection 
PRN pain 
for up to 
four weeks 
 
Placebo 
conservativ
e treatment 
consisting 
of 3L of 
H2O, 75 
mg 
diclofenac  
injection 
PRN pain 
Expulsio
n, 
expulsio
n time, 
pain 
quantifie
d by 
amount 
med use 
RC
T 
2 Spontane
ous stone 
expulsion
- 
statisticall
y 
significan
t 
difference 
b/w Tam 
and 
placebo 
 
statisticall
y 
significan
t 
difference 
b/w 
Alfazosin 
and 
placebo 
 
Stone 
expulsion 
time-  
statisticall
y 
significan
t 
difference 
b/w Tam 
and 
placebo 
 
statisticall
y 
significan
t 
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difference 
b/w 
alfazosin 
and 
placebo 
 
PAIN- 
Pain 
episodes 
tam- 0.52 
alf- 0.82 
placebo- 
5.5  
 
diclo 
injections 
tam- 0.88 
alf- 1 
placebo- 
6.2 
Porpiglia et 
al/ A second 
cycle of 
Tamsulosin 
in patients 
with distal 
ureteric 
stones: a 
prospective 
randomized 
trial 
2009 91 
patients 
with 
lower 
uretral 
stones 
between 
5mm-
10mm 
with 
radiograp
hic 
evidence 
who 
previousl
y failed a 
10 day 
MET trial 
with daily 
0.4 mg 
Tamsulos
in 
0.4 mg 
tamsulosin 
QD 
hydration 
75mg 
diclofenac 
inj PRN 
Conservati
ve 
treatment- 
hydration 
75mg 
diclofenac 
inj PRN  
Stone 
expulsio
n, time 
to 
expulsio
n, renal 
colic 
episodes   
RC
T 
2 Study 
showed 
statisticall
y 
significan
ce in 
stone 
expulsion
, but time 
to 
expulsion 
and renal 
colic 
episodes 
was not 
significan
t between 
the two 
groups.  
Also 
study did 
not report 
any 
significan
t SE of 
the 
groups. 
Sayed et al/ 2008 90 adult 0.4 mg Conservati Stone RC 2 Results of 
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Efficacy of 
Tamsulosin 
in medical 
expulsive 
therapy for 
distal 
ureteral 
calculi 
patients 
with 
5mm-
10mm 
stone 
with 
radiograp
hic 
evidence 
for four 
weeks 
tamsulosin 
daily 
2L of H2O/ 
day, 100 
mg 
diclofenac  
PRN pain 
for up to 
four weeks 
ve therapy- 
2 L 
ofH2O/day 
hydration, 
100 mg 
diclofenac  
PRN pain 
for up to 
four weeks 
 
expulsio
n, time 
to stone 
expulsio
n, pain 
episodes 
T stone 
expulsion
, time to 
expulsion
, and pain 
between 
tamsulosi
n group 
and 
conservati
ve 
therapy 
all 
statisticall
y 
significan
t 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
